|
May 17
|
Fortress Biotech First Quarter 2025 Earnings: Beats Expectations
|
|
May 16
|
New Strong Sell Stocks for May 16th
|
|
May 15
|
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 15
|
Fortress Biotech: Q1 Earnings Snapshot
|
|
May 15
|
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
|
|
May 14
|
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
|
|
May 13
|
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
|
|
Apr 9
|
This Fortress Biotech Insider Increased Their Holding By 26% Last Year
|
|
Mar 14
|
Biotech Alert: Searches spiking for these stocks today
|
|
Mar 12
|
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
|
|
Mar 10
|
Update: Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday
|
|
Mar 10
|
Sun Pharma to Acquire Checkpoint Therapeutics
|
|
Feb 27
|
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
|
|
Feb 11
|
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Feb 10
|
Mustang Bio Announces Closing of $8 Million Public Offering
|
|
Sep 26
|
Fortress Biotech to Participate in October 2024 Investor Conferences
|
|
Sep 20
|
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
|
|
Jul 25
|
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
|
|
Jul 25
|
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
|
Jun 24
|
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
|